Differences of the Effect of Ibandronate and Alendronate Sodium in Treatment of Postmenopausal Osteoporosis:Sys-tem Evaluation
XIE Heng-hu
WANG Qi-long
WANG Rong
Abstract：Objective To investigate the difference of curative effect of ibandronate and alendronate on postmenopa-usal osteoporosis. Methods By searching the RCT PubMed, BMA, EMbase, ASP, The Cochrane Library, EMCC, CBM, CNKI, CECDB, CQVIP, VIP database during August 1994 and November 2014 period, strict appraisal and data extraction on the quality of the included studies were evaluated, using Stata/SE version 12 software systematic evaluation of included stud-ies. Results Finally, 10 RCT articles were included with, a total of 725 cases, including 379 cases of the use of sodium ibandronate, 346 cases with alendronate sodium. The results showed that: compared with alendronate, BMD content in pa-tients with lumbar acid sodium ibandronate significantly increased 6 months after treatment [P=0. 174, I2 =29. 4%, WMD=0. 03, 95%CI= (0. 01, 0. 04)];fracture incidence within one year significantly decreased [P=5. 810, I2 =0, OR=0. 32, 95%CI=(0. 10, 1. 00)]. But 1 year after treatment of lumbar BMD and 6 months after treatment, the fracture rate was com-pared and system evaluation showed no significant differences between the two medications. Conclusion Sodium ibandronate in treatment of postmenopausal osteoporosis, can improve the lumbar BMD 6 months after treatment, reduce the risk of fracture within one year after treatment.
Keywords：OsteoporosisPostmenopausalAlendronateIbandronateTreatment outcome
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 96-101 )